(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 January 2011 (06.01.2011)

PCT

(10) International Publication Number
WO 2011/001169 A1

(51) International Patent Classification:
A61P 25/08 (2006.01) *A61K 31/352* (2006.01)

(21) International Application Number:
PCT/GB2010/051066

(22) International Filing Date:
29 June 2010 (29.06.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0911580.9 3 July 2009 (03.07.2009) GB

(71) Applicants *(for all designated States except US)*: **GW PHARMA LIMITED** [GB/GB]; Porton Down Science Park, Salisbury Wiltshire SP4 0JQ (GB). **OTSUKA PHARMACEUTICAL CO. LIMITED** [JP/JP]; 9, Kanda-Tsukasamachi 2-chome, Chiyoda-ku, Tokyo, 101-8535 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **WHALLEY, Ben** [GB/GB]; School of Pharmacy, University of Reading, Whiteknights, PO Box 226, Reading RG6 6AP (GB). **STEPHENS, Gary** [GB/GB]; School of Pharmacy, University of Reading, Whiteknights, PO Box 226, Reading RG6 6AP (GB). **WILLIAMS, Claire** [GB/GB]; School of Pharmacy, University of Reading, Whiteknights, PO Box 226, Reading RG6 6AP (GB). **GUY, Geoffrey** [GB/GB]; GW Pharmaceuticals Limited, Porton Down Science Park, Salisbury SP4 0JQ (GB). **WRIGHT, Stephen** [GB/GB]; GW Pharmaceuticals Limited, Porton Down Science Park, Salisbury SP4 0JQ (GB). **KIKUCHI, Tetsuro** [JP/JP]; Otsuka Pharmaceutical Company Limited, 2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo, 101-8535 (JP).

(74) Agent: **HARRISON GODDARD FOOTE**; 4th Floor, Merchant Exchange, 17-19 Whitworth Street West, Manchester M1 5WG (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2011/001169 A1

(54) **Title**: USE OF ONE OR A COMBINATION OF PHYTO-CANNABINOIDS IN THE TREATMENT OF EPILEPSY

(57) **Abstract**: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.